November 18, 2022 News by Patricia Valerio, PhD NervGen Completes Dosing Another Group With MS Candidate NVG-291 Dosing of NVG-291, NervGen Pharmaās investigational therapy for multiple sclerosis (MS) and other nervous system diseases, was completed in the third and final group of healthy postmenopausal women in a Phase 1 clinical trial. āCompleting the dosing of the final [group] of postmenopausal females in the MAD [multiple…
May 13, 2022 News by Lindsey Shapiro, PhD NervGen Cleared to Enroll Final Group in Trial of NVG-291 NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an investigational treatment for multiple sclerosis (MS) and other nervous system diseases. A safety review committee cleared the…
April 8, 2022 News by Marisa Wexler, MS #AAN2022 ā Phase 1 Data Shows NVG-291 Safe; Trial in MS Patients Anticipated NVG-291, an experimental therapy designed to promote nervous system repair, has so far been well tolerated in an ongoing Phase 1 study with healthy volunteers. “The Phase 1 study is progressing very well, and we are encouraged by the data we are seeing so far,” Daniel Mikol, MD, PhD, chief…
March 21, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: SPMS Transition, NVG-291, PIPE-307, Foralumab MS Doctors, Nurses in UK Struggle With Marking Transition to SPMS The issue highlighted in this story isn’t just a problem in the U.K.; it’s a universal MS problem. People with MS often ask how they will know when their illness has transitioned from relapsing to progressive. I respond…
March 17, 2022 News by Patricia Inacio, PhD NervGen Cleared to Enroll 2nd MAD Group in NVG-291 Trial NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion of its Phase 1 clinical trial of NVG-291, a therapeutic candidate for multiple sclerosis (MS). The trial’s Safety Review Committee approved the second group after seeing promising safety data…
January 3, 2022 News by Patricia Inacio, PhD Ascending Dosing Will Start in Trial of NVG-291 in Healthy Volunteers NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291…
November 5, 2021 News by Steve Bryson, PhD Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People A single dose of NVG-291, a potential nerve repair therapy for multiple sclerosis (MS), was safe and well-tolerated among healthy volunteers in a Phase 1 safety trial, and was found to have favorable pharmacological properties, new data show. Given the positive results thus far, a safety committee supervising…
August 23, 2021 News by Marta Figueiredo, PhD Top-line Data on NVG-291 in Healthy Volunteers Expected This Year NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 ā its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions ā in healthy volunteers is going according to plan, with early top-line data expected later this year. āThe…
July 19, 2021 News by Marisa Wexler, MS NervGen Sets Advisory Board to Support Upcoming NVG-291 Trial NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who will work with the company as it prepares to start a Phase 2 clinical trial next year testing its lead compound, NVG-291, in people with MS. “We are honored to…